| 西妥昔单抗联合三维适形放疗在中晚期食管癌患者中的疗效 |
| |
| 引用本文： | 吴珊珊,马文君. 西妥昔单抗联合三维适形放疗在中晚期食管癌患者中的疗效[J]. 国际医药卫生导报, 2022, 28(4): 548-551. DOI: 10.3760/cma.j.issn.1007-1245.2022.04.026 |
| |
| 作者姓名： | 吴珊珊 马文君 |
| |
| 作者单位： | 南阳市第一人民医院肿瘤二科，南阳 473000 |
| |
| 摘 要： | 目的:探讨西妥昔单抗联合三维适形放疗在中晚期食管癌患者中的疗效及对血清肿瘤标志物水平、新生血管指标水平、生存情况的影响。方法:回顾性分析选取南阳市第一人民医院2020年1月至2021年8月收治的106例中晚期食管癌患者作为研究对象，分析患者的病历资料后，根据治疗方案的不同将患者分对照组和观察组各53例。对照组接受三维适...
|
| 关 键 词： | 食管癌 西妥昔单抗 三维适形放疗 血清肿瘤标志物 新生血管 不良反应 |
| 收稿时间： | 2021-10-27 |
Efficacy of cetuximab combined with three-dimensional conformal radiotherapy for patients with advanced esophageal cancer |
| |
| Wu Shanshan,Ma Wenjun. Efficacy of cetuximab combined with three-dimensional conformal radiotherapy for patients with advanced esophageal cancer[J]. International Medicine & Health Guidance News, 2022, 28(4): 548-551. DOI: 10.3760/cma.j.issn.1007-1245.2022.04.026 |
| |
| Authors: | Wu Shanshan Ma Wenjun |
| |
| Affiliation: | No.2 Department of Oncology, Nanyang First People's Hospital, Nanyang473000, China |
| |
| Abstract: | Objective To investigate the efficacy of cetuximab combined with three-dimensionalconformal radiotherapy in the treatment of advanced esophageal cancer and itsinfluence on serum tumor markers levels, neovascularization indexes levels, andsurvival. Methods A total of 106patients with advanced esophageal cancer admitted to Nanyang First People'sHospital from January 2020 to August 2021 was selected as the research objects.After analyzing the patients' medical records, the patients were divided into acontrol group and an observation group according to different treatmentoptions, with 53 cases in each group. The control group receivedthree-dimensional conformal radiotherapy, and the observation group receivedcetuximab combined with three-dimensional conformal radiotherapy. The controlgroup included 30 females and 23 males, aged (58.69±1.28) years; theobservation group included 31 females and 22 males, aged (57.96±1.32) years.The therapeutic efficacy, serum tumor markers levels [carbohydrate antigen 125(CA125), cytokeratin protein fragment 19 (CYFA21-1), and serum carcinoembryonicantigen (CEA)], neovascularization indexes levels [transforming growth factorβ1 (TGF-β1) and vascular endothelial growth factor (VEGF)], survival status,and adverse reactions were compared between the two groups. The measurementdata were tested by independent sample t test and the count data were tested by χ2 test. Results The total effective rate of the observation group was 75.47% (40/53),higher than 49.06% (26/53) in the control group (P<0.05). There were no statistically significant differences inthe serum tumor markers between the two groups before treatment (all P>0.05), and the levels of CA125,CYFA21-1, and CEA in the observation group were lower than those in the controlgroup after treatment (all P<0.05).There were no statistically significant differences in TGF-β1 andVEGF between the two groups before treatment (both P>0.05), and the levels of TGF-β1 and VEGF in the observationgroup were lower than those in the control group after treatment (both P<0.05). The survival rate of theobservation group (60.38%, 32/53) was higher than that of the control group(37.74%, 20/53) (P<0.05). Therewas no statistically significant difference in the incidence of adversereactions between the observation group (18.87%, 10/53) and the control group(22.64%, 12/53) (P>0.05). Conclusion Cetuximab combinedwith three-dimensional conformal radiotherapy for patients with advancedesophageal cancer can significantly improve their levels of serum tumor markersand neovascularization indicators, increase the survival rate, which is safeand effective. |
| |
| Keywords: | Esophageal cancer Cetuximab Three-dimensional conformal radiotherapy Serum tumor markers Neovascularization Adverse reactions |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《国际医药卫生导报》浏览原始摘要信息 |
|
点击此处可从《国际医药卫生导报》下载免费的PDF全文 |
|
